Premium
SAKK 36/13 ‐ IBRUTINIB PLUS BORTEZOMIB AND IBRUTINIB MAINTENANCE FOR RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA: FINAL REPORT OF A PHASE I/II TRIAL OF THE EUROPEAN MCL NETWORK
Author(s) -
Novak U.,
Fehr M.,
Schär S.,
Dreyling M.,
Scheubeck G.,
Ramadan S.,
Zucca E.,
Zander T.,
Hess G.,
Mey U.,
Ferrero S.,
Mach N.,
Boccomini C.,
Böttcher S.,
Voegeli M.,
Cairoli A.,
Menter T.,
Dirnhofer S.,
Gadient S.,
Eckhardt K.,
Driessen C.,
Renner C.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.62_2879
Subject(s) - ibrutinib , mantle cell lymphoma , medicine , bortezomib , lenalidomide , phases of clinical research , oncology , refractory (planetary science) , clinical endpoint , proteasome inhibitor , lymphoma , chemotherapy , clinical trial , pharmacology , multiple myeloma , leukemia , physics , chronic lymphocytic leukemia , astrobiology